Apitegromab, Muscle-directed Therapy for SMA, Put on FDA Fast Track episode artwork

EPISODE · Jun 4, 2021 · 6 MIN

Apitegromab, Muscle-directed Therapy for SMA, Put on FDA Fast Track

from The Spinal Muscular Atrophy Podcast with Kevin Schaefer · host SMA News Today

SMA News Today’s multimedia associate, Price Wooldridge, discusses Apitegromab being granted a fast track designation by the U.S. Food and Drug Administration.DeAnn Runge talks about her upcoming appointment with her neurologist to discuss continuing with Evrysdi or switching back to Spinraza. She dreads making the wrong decision. Are you interested in learning more about spinal muscular atrophy? If so, please visit https://smanewstoday.com/

Episode metadata supplied by the publisher feed · Published Jun 4, 2021

Embed this episode

Ready to play

Apitegromab, Muscle-directed Therapy for SMA, Put on FDA Fast Track

0:00 6:29

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The Spinal Muscular Atrophy Podcast with Kevin Schaefer?

This episode is 6 minutes long.

When was this The Spinal Muscular Atrophy Podcast with Kevin Schaefer episode published?

This episode was published on June 4, 2021.

Can I download this The Spinal Muscular Atrophy Podcast with Kevin Schaefer episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!